KALA

KALA BIO Inc

KALA BIO, Inc. (NASDAQ:KALA - Get Free Report) was the target of a significant increase in short interest in the month of March. As of March 13th, there was short interest totaling 6,830,724 shares...

KALA BIO (NASDAQ:KALA) will be releasing its Q4 2025 earnings before the market opens on Thursday, March 26. (View Earnings Report at...

KALA BIO, Inc. (NASDAQ:KALA - Get Free Report) saw a significant growth in short interest during the month of February. As of February 27th, there was short interest totaling 975,765 shares, a growth...

A fresh wave of developments across artificial intelligence, healthcare technology, and digital infrastructure is reinforcing a central theme dominating markets: the rapid convergence of AI with data-heavy industries. From biotech platforms deploying autonomous agents to data-center integrators scaling AI infrastructure, companies are positioning themselves to capture value from the next phase of the technology cycle. $KALA, $TGNT, $DOMO, $TSSI, $CYN, $AUNA, $VACHU

The company said that it is ready to deploy its new AI platform, Researgency, within 14 days.

KALA BIO, Inc. (NASDAQ:KALA - Get Free Report) has been assigned a consensus rating of "Hold" from the six ratings firms that are presently covering the stock, MarketBeat Ratings reports. One...

A rescue financing and loan settlement halted an impending asset seizure after Oxford’s default.

KALA BIO stock plunges 88% after its KPI-012 eye disorder study fails to meet goals, forcing the company to scrap its pipeline and explore strategic options.

The firm stated that its KPI-012 failed in a mid-stage clinical trial and announced that it intends to preserve cash, including by laying off some of its workforce and deploying other cost-saving measures.